Back

Efficacy and safety of potent p2y12 inhibitors versus clopidogrel in complex percutaneous coronary intervention: a systematic review and meta-analysis

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Pharmacotherapy in acute coronary syndromes (5) Pharmacotherapy ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Francesco Stabile

University Hospital Paolo Giaccone, Palermo (Italy)

3 More presentations in this session

Presentation thumbnail
Prophylactic anticoagulation for left ventricular thrombus in patients with anterior myocardial infarction
Doctor A. Gajulapalli (Stony Brook, US)
Abstract Slides Video
Presentation thumbnail
High-intensity lipid-lowering therapy accelerates early plaque regression: a FLOWPROMOTE sub study.
Doctor N. Iraqi (Aarhus, DK)
Abstract Slides Video
Presentation thumbnail
Impact of beta-blocker carvedilol versus Bisoprolol prescription at discharge on long-term clinical outcomes in STEMI patients with preserved LVEF treated with drug-eluting stents
Professor S. Park (Seoul, KR)
Abstract Slides Video

Access the full session

Session thumbnail
Pharmacotherapy in acute coronary syndromes (5)

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
Ticagrelor or clopidogrel in atrial fibrillation patients undergoing percutaneous coronary intervention for myocardial infarction
thumbnail
Congress Presentation
Comparison of ticagrelor and prasugrel just before PCI in NSTE acute coronary syndromes, LIKE-ACCOAST analysis
thumbnail
Congress Presentation
Clinical impact of high platelet reactivity in patients with atrial fibrillation and concomitant percutaneous coronary intervention on dual or triple antithrombotic therapy

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources